| Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates |
- Progression-free survival data from more than 30 patients with first line pancreatic cancer in the ongoing Phase 2a trial of IMM-1-104 trial planned for announcement in 2Q'25 - - Reported positive data from the Company's ongoing Phase 2a trial of lead program IMM-1-104, including encouraging responses in combination with chemotherapy in first-line pancreatic cancer, and as monotherapy in second-line pancreatic cancer - - Announced clinical trial supply agreement with Regeneron Pharmaceuticals to evaluate IMM-1-104 in combination with Libtayo® (cemiplimab) in non-small cell lung cancer - - Named industry veteran Dr. Igor Matushansky as Chief Medical Officer, to lead clinical efforts as the Company ramps up planning for Phase 3 trial in first line pancreatic cancer - - Cash runway extended into 2026 - CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients, today reported financial results for the first quarter ended March 31, 2025, and provided several business updates. |
globenewswire.com |
2025-05-05 20:05:00 |
Czytaj oryginał (ang.) |
| Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference |
CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients, today announced that management will present at the 24th Annual Needham Virtual Healthcare Conference, which is taking place from April 7-10, 2025, to discuss the company's pipeline, platform, and business strategy. |
globenewswire.com |
2025-04-02 12:00:00 |
Czytaj oryginał (ang.) |
| Immuneering Corporation Announces Grant of Inducement Award |
CAMBRIDGE, Mass., March 21, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients, previously announced on March 20, 2025, that Igor Matushansky, M.D. |
globenewswire.com |
2025-03-21 18:30:00 |
Czytaj oryginał (ang.) |
| Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates |
- Reported positive data updates from its ongoing Phase 2a trial of lead program IMM-1-104, including encouraging responses in combination with chemotherapy in first-line pancreatic cancer - - Announced a clinical trial supply agreement with Regeneron Pharmaceuticals to evaluate IMM-1-104 in combination with Libtayo® (cemiplimab) in non-small cell lung cancer - - Additional IMM-1-104 Phase 2a data updates and initiation of new IMM-1-104 combination arms expected in 2025; planning underway for potential IMM-1-104 global pivotal trial - - Named industry veteran Dr. Igor Matushansky as Chief Medical Officer - - Cash runway extended into 2026 - CAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided recent business updates. |
globenewswire.com |
2025-03-20 18:05:00 |
Czytaj oryginał (ang.) |
| Immuneering Names Dr. Igor Matushansky as Chief Medical Officer |
Industry veteran brings extensive oncology drug development expertise and experience in clinical treatment of cancer patients Dr. Matushansky joins as Immuneering plans to present updated data from Phase 2a trial of IMM-1-104 in pancreatic cancer in Q2 2025 CAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Immuneering (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients, today announced that Igor Matushansky, MD, PhD, has joined the company as Chief Medical Officer. |
globenewswire.com |
2025-03-20 09:00:00 |
Czytaj oryginał (ang.) |
| Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference |
CAMBRIDGE, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients, today announced that management will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference, which is taking place virtually from February 11-12, 2025, to discuss the company's pipeline, platform, and business strategy. |
globenewswire.com |
2025-02-03 18:05:00 |
Czytaj oryginał (ang.) |
| Why Is Immuneering Stock Trading Higher On Tuesday? |
On Tuesday, Immuneering Corporation IMRX revealed data updates from three pancreatic cancer arms of its ongoing Phase 2a trial of lead program IMM-1-104 and plans to expand the Phase 2a trial to include three additional combination arms. |
benzinga.com |
2025-01-07 11:28:53 |
Czytaj oryginał (ang.) |
| Immuneering Launches Pancreatic Cancer Advisory Board |
- Establishment reflects the clinical progress of IMM-1-104 and its promise in pancreatic cancer - - Follows recent Orphan Drug designation in pancreatic cancer and Fast Track designations in first- and second-line pancreatic cancer for IMM-1-104 - CAMBRIDGE, Mass., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced the formation of its Pancreatic Cancer Advisory Board. |
globenewswire.com |
2024-12-19 10:00:00 |
Czytaj oryginał (ang.) |
| Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday? |
Morgan Stanley downgraded Amicus Therapeutics Inc FOLD. Over the last year, the company has executed well commercially, met its goals financially by achieving nonGAAP profitability for 2024, and settled its Galafold patent litigation with Teva Pharmaceutical Industries Ltd. |
benzinga.com |
2024-12-13 16:10:50 |
Czytaj oryginał (ang.) |
| Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma |
- IMM-1-104 has the potential to benefit melanoma patients who have progressed on or are intolerant to immune checkpoint inhibitors - - IMM-1-104 was observed to be uniquely well tolerated in Phase 1 data shared at ESMO 2024, relative to MEK inhibitors currently used to treat melanoma - - Melanoma patients actively enrolling in one of five arms in the company's ongoing Phase 2a clinical study of IMM-1-104 - CAMBRIDGE, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its lead clinical-stage program, IMM-1-104, as a treatment for patients with unresectable or metastatic NRAS-mutant melanoma who have progressed on or are intolerant to PD-1/PD-L1 based immune checkpoint inhibitors. |
globenewswire.com |
2024-12-12 10:00:00 |
Czytaj oryginał (ang.) |
| Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference |
CAMBRIDGE, Mass., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that management will present at the Piper Sandler 36th Annual Healthcare Conference, which is taking place at the Lotte New York Palace in New York City from December 3-5, 2024, to discuss the company's pipeline, platform, and business strategy. |
globenewswire.com |
2024-11-27 10:00:00 |
Czytaj oryginał (ang.) |
| Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates |
- Announced Positive Initial Data, Including Complete and Partial Responses, with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients - - Granted FDA Orphan Drug Designation for IMM-1-104 in the Treatment of Pancreatic Cancer and Fast Track Designation in First-line Pancreatic Cancer - - Initial Data From At Least One Additional Arm of the Phase 2a Portion of the IMM-1-104 Phase 1/2a Trial Expected by Year End - - Cash Runway into Fourth Quarter 2025 - CAMBRIDGE, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today reported financial results for the third quarter ended September 30, 2024, and provided business updates. |
globenewswire.com |
2024-11-13 18:05:00 |
Czytaj oryginał (ang.) |
| IMRX Stock Up on FDA's Orphan Drug Tag for Pancreatic Cancer Drug |
The FDA bestows an orphan drug designation to Immuneering's lead candidate, IMM-1-104, for the treatment of pancreatic cancer. Shares rise. |
zacks.com |
2024-10-16 15:25:22 |
Czytaj oryginał (ang.) |
| IMRX Stock Soars on Upbeat Efficacy Data From Pancreatic Cancer Study |
Immuneering stock soars 41% as lead drug combo regimen shows superior initial efficacy in the first-line treatment of pancreatic cancer in a mid-stage study. |
zacks.com |
2024-09-16 14:15:34 |
Czytaj oryginał (ang.) |
| Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients |
Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line |
globenewswire.com |
2024-09-12 20:05:00 |
Czytaj oryginał (ang.) |
| Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates |
- Enrollment progressing well across all arms in the IMM-1-104 Phase 2a Trial, with Initial Data from Multiple Arms Expected in 2H 2024 - - Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer - - Preclinical Data Presented at AACR Demonstrates that Combining IMM-1-104 with Chemotherapies Used in the Treatment of First-line Pancreatic Cancer Yields Deeper and More Durable Tumor Growth Inhibition Than Either Treatment Alone - - Initial PK, PD and Safety Data from Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations expected in 2H 2024 - CAMBRIDGE, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today reported financial results for the second quarter ended June 30, 2024, and provided business updates. |
globenewswire.com |
2024-08-06 20:05:00 |
Czytaj oryginał (ang.) |
| Why is Immuneering (IMRX) Stock Up 24% Today? |
Various names in the biotech sector are seeing big moves in today's session, as investors are clearly interested in rotation into a number of higher-growth small-cap stocks. Immuneering (NASDAQ: IMRX ) is certainly one such company generating outsized interest today. |
investorplace.com |
2024-08-01 19:36:31 |
Czytaj oryginał (ang.) |
| Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer |
- IMM-1-104 Fast Track designation now granted for the treatment of both first and second-line pancreatic ductal adenocarcinoma (PDAC); provides potential to accelerate IMM-1-104's path to U.S. FDA submission for PDAC - - Phase 2a trial of IMM-1-104 includes multiple arms open to first-line pancreatic cancer patients, as well as arms open to patients with second-line pancreatic cancer, RAS-mutant melanoma, and RAS-mutant lung cancer - - Company expects initial data from multiple arms of its Phase 2a clinical trial in the second half of 2024 - CAMBRIDGE, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for its lead clinical-stage program, IMM-1-104, as a first-line treatment for patients with pancreatic ductal adenocarcinoma (PDAC). |
globenewswire.com |
2024-07-31 20:05:00 |
Czytaj oryginał (ang.) |
| 3 Penny Stocks With 735% Average Upside, According to Wall Street |
With the third quarter in full swing, the bulls have not lost their grip on equities. |
247wallst.com |
2024-07-09 14:47:15 |
Czytaj oryginał (ang.) |
| Immuneering to Present at the Jefferies Global Healthcare Conference |
CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that management will participate in the Jefferies Global Healthcare Conference, which is taking place at the Marriott Marquis in New York City from June 5-6, 2024, to discuss the company's pipeline, platform, and business strategy. |
globenewswire.com |
2024-05-29 20:05:00 |
Czytaj oryginał (ang.) |
| Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates |
- Reported Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors - - First Patient Dosed in Phase 2a Portion of Phase 1/2a Clinical Trial of IMM-1-104; Initial Data from Multiple IMM-1-104 Phase 2a Arms Expected in 2024 - - Presented Preclinical Data at AACR Demonstrating that Combining IMM-1-104 with Chemotherapies Used in The Treatment of First-line Pancreatic Cancer Yielded Deeper and More Durable Tumor Growth Inhibition Than Either Treatment Alone - - First Patient Dosed in Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations; Initial PK, PD and safety data expected in 2024 - CAMBRIDGE, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today reported financial results for the first quarter ended March 31, 2024, and provided business updates. |
globenewswire.com |
2024-05-07 20:05:00 |
Czytaj oryginał (ang.) |
| Immuneering Recognizes Melanoma Awareness Month |
- Two clinical stage product candidates in development for the treatment of melanoma - - RAS mutant melanoma represents one of five arms in the company's ongoing Phase 2a clinical study of IMM-1-104 - - Melanoma also being evaluated in ongoing Phase 1/2a clinical study of IMM-6-415 in patients with advanced solid tumors harboring RAF or RAS mutations - - Immuneering expects initial data from multiple IMM-1-104 Phase 2a arms in 2024 - CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, recognizes the importance of early detection and treatment during Melanoma Awareness Month, and highlights RAS mutant melanoma as the focus of one of the five arms in its ongoing Phase 2a clinical study for its lead program IMM-1-104. |
globenewswire.com |
2024-05-06 20:30:00 |
Czytaj oryginał (ang.) |
| IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models |
- Preclinical data presented at AACR demonstrate that combining IMM-1-104 with chemotherapies used in the treatment of first-line pancreatic cancer yielded deeper and more durable tumor growth inhibition than either treatment alone - - Patients are now on treatment in multiple arms of the ongoing Phase 2a trial, including multiple patients with pancreatic cancer who are being treated with IMM-1-104 in combination with chemotherapy in the first-line setting - - Immuneering expects initial data from multiple IMM-1-104 Phase 2a arms in 2024 - CAMBRIDGE, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today presented preclinical data at the American Association for Cancer Research (AACR) Annual Meeting, which the company views as supportive of its ongoing Phase 2a clinical trial of IMM-1-104 in RAS-mutated advanced or metastatic solid tumors. |
globenewswire.com |
2024-04-09 16:00:00 |
Czytaj oryginał (ang.) |
| Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference |
CAMBRIDGE, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that management will participate in the 23rd Annual Needham Virtual Healthcare Conference, taking place April 8-11, 2024, to discuss the company's pipeline, platform, and business strategy. |
globenewswire.com |
2024-04-03 20:05:00 |
Czytaj oryginał (ang.) |
| Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations |
- Deep Cyclic Inhibitor of the MAPK pathway demonstrated strong tumor growth inhibition in preclinical studies of RAF or RAS mutant tumors, both as monotherapy and in combination - - Phase 1 portion of the Phase 1/2a trial designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of IMM-6-415 and establish a candidate recommended Phase 2 dose (RP2D) - -Initial PK, PD and safety data expected in 2024 - CAMBRIDGE, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that the first patient has been dosed in its Phase 1/2a trial of IMM-6-415 to treat advanced solid tumors with RAF or RAS mutations. |
globenewswire.com |
2024-03-27 10:00:00 |
Czytaj oryginał (ang.) |
| Immuneering: Phase 1 Data Release IMM-1-104 Leads To Additional 2024 Milestone |
Positive safety and anti-tumor activity released from phase 1 portion of phase 1/2a study, using IMM-1-104 for the treatment of patients with RAS-mutant solid tumors. Additional expansion cohort results from the phase 2 portion of the phase 1/2a study, using IMM-1-104 for the treatment of patients with RAS-mutant solid tumors, expected later in 2024. IMM-6-415 is another MAPK pathway targeting drug, but is able to target either RAS or RAF solid tumors; Dosing of first patient in phase 1 study expected in March 2024. |
seekingalpha.com |
2024-03-19 04:19:36 |
Czytaj oryginał (ang.) |
| Immuneering (IMRX) Plummets 71% in One Week: Here's Why |
Immuneering (IMRX) plunges after multiple Wall Street analysts downgraded the stock on lackluster results from an early-stage study evaluating its lead drug across advanced RAS-mutant solid tumors. |
zacks.com |
2024-03-18 14:06:08 |
Czytaj oryginał (ang.) |